Maintain Elahere access for ovarian cancer patients
Join 1 people who have already added their signatures to this Open Letter. Please add you name today and help us reach 100 signatures.
- Secretary of State for Health and Social Care
- Vice President and General Manager of AbbVie UK (pharmaceutical company responsible for Elahere)
We passionately believe that patients with ovarian cancer should have access to the best possible treatment targeted to their needs. We therefore call on NHS England, the Department for Health and Social Care and AbbVie, the manufacturer of Elahere, to urgently reopen discussions with one another, to find a solution that ensures women are able to access this vital treatment.
As you will know, ovarian cancer is a devastating disease and women with the platinum resistant form have very limited treatment options. Those that have received this innovative treatment during clinical trials have reported significant benefits. It would be deeply disappointing if future ovarian cancer patients were not given the option of this treatment simply because NHS England, DHSC and AbbVie were unable to resolve disagreements on price.
Please give hope to women who will be diagnosed with platinum resistant ovarian cancer: please return to the negotiating table.